<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00737594</url>
  </required_header>
  <id_info>
    <org_study_id>SPH0721</org_study_id>
    <nct_id>NCT00737594</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sucampo Pharma Americas, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sucampo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at
      two dose levels) as compared to placebo for lowering portal hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to enroll a suitable number of qualified subjects.
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) After Four (4) Weeks of Treatment</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo TID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive matching placebo capsules three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 mcg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 12 mcg Cobiprostone TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18 mcg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 18 mcg Cobiprostone TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules for oral administration</description>
    <arm_group_label>Placebo TID</arm_group_label>
    <other_name>Matching placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobiprostone</intervention_name>
    <description>Cobiprostone capsules for oral administration</description>
    <arm_group_label>12 mcg TID</arm_group_label>
    <arm_group_label>18 mcg TID</arm_group_label>
    <other_name>Experimental product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &gt;= 18 years of age.

          -  Patient has clinical and/or pathological diagnosis of intra-hepatic portal
             hypertension.

          -  Patient has clinical diagnosis of cirrhosis.

          -  Patient has undergone variceal banding.

        Exclusion Criteria:

          -  Patient has a Child-Pugh score &gt;12.

          -  Patient has portal hypertension resulting from hepatic vein obstruction, portal vein
             occlusion, schistosomiasis, portal vein thrombosis, splenic vein thrombosis, or
             Budd-Chiari syndrome.

          -  Variceal banding procedure was performed within 1 month of the screening visit.

          -  Patient has active or recurrent variceal bleeding, or has had variceal bleeding within
             the 12 weeks prior to screening.

          -  Patient is unwilling to discontinue use of vasoactive drugs from the screening visit
             through the end of the study.

          -  Patient has hepatocellular carcinoma that is being medically treated or is advanced.

          -  Patient has impaired renal function (i.e., serum creatinine concentration &gt;1.8 mg/dl)

          -  Patient has a history of liver transplant, or is expected to receive a liver
             transplant during the study period.

          -  Patient has undergone a gastrointestinal or abdominal surgical procedure within 90
             days prior to the Screening Visit, or has had a bowel resection at any time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>August 15, 2008</study_first_submitted>
  <study_first_submitted_qc>August 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2008</study_first_posted>
  <results_first_submitted>February 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2016</results_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>9 participants were recruited, but the study terminated before data were collected</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: 0 mcg capsules three times daily (TID)</description>
        </group>
        <group group_id="P2">
          <title>12 mcg TID</title>
          <description>Cobiprostone 36 mcg
Cobiprostone: 12 mcg cobiprostone (capsules) three times daily (TID)</description>
        </group>
        <group group_id="P3">
          <title>18 mcg TID</title>
          <description>Cobiprostone 54 mcg
Cobiprostone: 18 mcg cobiprostone (capsules) three times daily (TID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study terminated before data were collected</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: 0 mcg capsules three times daily (TID)</description>
        </group>
        <group group_id="B2">
          <title>12 mcg TID</title>
          <description>Cobiprostone 36 mcg
Cobiprostone: 12 mcg cobiprostone (capsules) three times daily (TID)</description>
        </group>
        <group group_id="B3">
          <title>18 mcg TID</title>
          <description>Cobiprostone 54 mcg
Cobiprostone: 18 mcg cobiprostone (capsules) three times daily (TID)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) After Four (4) Weeks of Treatment</title>
        <time_frame>4 weeks</time_frame>
        <population>Study terminated early, data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: 0 mcg capsules three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>12 mcg TID</title>
            <description>Cobiprostone 36 mcg
Cobiprostone: 12 mcg cobiprostone (capsules) three times daily (TID)</description>
          </group>
          <group group_id="O3">
            <title>18 mcg TID</title>
            <description>Cobiprostone 54 mcg
Cobiprostone: 18 mcg cobiprostone (capsules) three times daily (TID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) After Four (4) Weeks of Treatment</title>
          <population>Study terminated early, data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The trial terminated before data were collected</time_frame>
      <desc>The trial terminated before data were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: 0 mcg capsules three times daily (TID)</description>
        </group>
        <group group_id="E2">
          <title>12 mcg TID</title>
          <description>Cobiprostone 36 mcg
Cobiprostone: 12 mcg cobiprostone (capsules) three times daily (TID)</description>
        </group>
        <group group_id="E3">
          <title>18 mcg TID</title>
          <description>Cobiprostone 54 mcg
Cobiprostone: 18 mcg cobiprostone (capsules) three times daily (TID)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial terminated before data were collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt Pharmaceuticals</organization>
      <phone>800-556-3314 ext 5</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

